Oncology News | pharmaphorum

News

Merck & Co's Keytruda approved for second "tumour agnostic" ...

Merck & Co’s Keytruda cancer immunotherapy has been approved by the FDA in another “tumour agnostic” use, in patients with high levels of mutation.

News

Regeneron gets closer to ISA Pharma with new immuno-oncology...

Regeneron has doubled down in its ongoing collaboration with ISA Pharma, taking a bigger stake in the Dutch biotech and cueing up a third trial of their immuno-oncology combina

News

Royalty Pharma shares surge 59% after $2.2 billion IPO

Biopharma initial public offerings are back with a bang after a coronavirus pandemic lull, as Royalty Pharma raised a record-breaking $2.2 billion from the sale of 77 million s

News

Agios up as FDA gives Thermo Fisher glioma test breakthrough...

Shares in Agios Pharma ticked upwards after the FDA awarded breakthrough status to a companion diagnostic to vorasidenib, its experimental drug for brain cancer.

News

NICE backs funding for Roche's lung cancer drug after price ...

NICE has recommended NHS funding for Roche’s Rozlytrek (entrectinib) as a treatment option for advanced non-small cell lung cancer with a rare mutation in final draft guidance.

News

Scopus Bio preps trials of gene-silencing immuno-oncology dr...

Scopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start clinical testing in lymphoma patients later this year.

Merck & Co's Keytruda approved for second "tumour agnostic" ...

Regeneron gets closer to ISA Pharma with new immuno-oncology...

Royalty Pharma shares surge 59% after $2.2 billion IPO

Agios up as FDA gives Thermo Fisher glioma test breakthrough...

NICE backs funding for Roche's lung cancer drug after price ...

Scopus Bio preps trials of gene-silencing immuno-oncology dr...

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks